pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Enveda secures $311 million in third consecutive megaround to advance discovery and weight-maintenance programs

Sep 23, 2026·read at Endpoints ↗DealPositive

Enveda, a biotech startup operating out of Colorado and India, announced a new financing round on September 23, 2026.

The company raised $311 million, marking its third large-scale funding round in as many years.

The capital will be used to advance its discovery platform that mines plant and microbe chemistry and to develop drug candidates aimed at weight maintenance.

The infusion of funds underscores continued investor interest in Enveda's approach and supports ongoing research and development activities.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Enveda raises its third megaround for I&I and weight maintenance drug candidates”

read at Endpoints ↗
91 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoChinese vaccine scandal leads to life sentence; Flagship wins defense contractEndpoints
  • 2h agoRoivant reports Phase 2b lupus failure for an FcRn drugEndpoints
  • 4h agoIn a changed world for cystic fibrosis, a family's fight reveals a new gap in careEndpoints
  • 4h agoAI startup Basecamp Research raises $140M Series C, shares pipelineEndpoints
  • 7h agoRoche kidney drug's Phase 3 win sets up path to accelerated approvalEndpoints